Proactive Investors - Run By Investors For Investors

Instem welcomes significant contract extension for SEND platform

Phil Reason, chief executive at Instem Plc (LON:INS), discusses with Proactive's Polly Middlehurst a significant contract extension from a company using their SEND platform.

The client, described as a top-five pre-clinical contract research organisation, has increased the size of the deal by US$400,000 to US$500,000.

Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full INS profile View Profile

Instem Plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use